APA (7th ed.) Citation

L, H., HS, R., P, S., S, S., VK, G., P, M., . . . P, T. (2026). Real-world postprogression outcomes after first-line treatment with ribociclib plus aromatase inhibitor versus aromatase inhibitor alone in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer in the United States of America. ESMO open, 11(7), 108243. https://doi.org/10.1016/j.esmoop.2026.108243

Chicago Style (17th ed.) Citation

L, Hart, et al. "Real-world Postprogression Outcomes After First-line Treatment with Ribociclib Plus Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Patients with Hormone Receptor-positive/human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in the United States of America." ESMO Open 11, no. 7 (2026): 108243. https://doi.org/10.1016/j.esmoop.2026.108243.

MLA (9th ed.) Citation

L, Hart, et al. "Real-world Postprogression Outcomes After First-line Treatment with Ribociclib Plus Aromatase Inhibitor Versus Aromatase Inhibitor Alone in Patients with Hormone Receptor-positive/human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in the United States of America." ESMO Open, vol. 11, no. 7, 2026, p. 108243, https://doi.org/10.1016/j.esmoop.2026.108243.